Last week, OneMedRadio spoke with Immune Pharmaceuticals founder and CEO Dr. Daniel Teper and Epicept Corporation President and CEO Robert Cook, to discuss the merger and the clinical focus of the merged company going forward.
Ceplene is administered for maintenance of first remission in patients with AML, the most common type of Leukemia in adults.
OneMedPlace announced today that its “OneMedForum 2011” business development and finance conference for emerging healthcare and life science companies will be held January 11-13, 2011, in San Francisco at the Sir Francis Drake Hotel.
China Analyst, a financial information website focused on U.S.-listed Chinese stocks, recently released its list of the top 10 pharmaceutical stocks with the highest upside.
EpiCept’s lead product, Ceplene, is approved for marketing in the EU for the maintenance of first remission in patients with acute myeloid leukemia.
Copyright © 2025 | WordPress Theme by MH Themes